Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas

Annals of Oncology : Official Journal of the European Society for Medical Oncology
R PalumboS Toma

Abstract

Ifosfamide has important activity in pretreated soft tissue sarcomas (STS), and recent data support a clinically significant dose-response relationship for this agent. Administration by continuous infusion and hematopoietic support have rendered dose intensification regimens possible by reducing both hematologic and non-hematologic toxicities. The optimal dose and schedule of ifosfamide when given at high doses remain to be defined. In a previous phase I study, we demonstrated the feasibility of a continuous infusion (c.i.) high-dose ifosfamide (HDI) regimen in the ambulatory setting for patients with advanced solid tumors. The objective of the present phase II study was to assess the antitumor activity and toxicity of such a schedule in patients with advanced pretreated STS. Thirty-eight patients with advanced and/or metastatic STS, all pretreated with an anthracycline with or without standard-dose ifosfamide, were treated. Ifosfamide was given by c.i. at a dose of 3.5 g/m2/day over four consecutive days, with equidose mesna uroprotection over five days. G-CSF was added at a dose of 200 micrograms/m2/day subcutaneously from day 6 to day 12. Cycles were repeated every three weeks in the outpatient setting. A total of 159 cycles...Continue Reading

Citations

Aug 20, 2002·The Oncologist·Alexander I Spira, David S Ettinger
Sep 28, 2007·Investigational New Drugs·Paolo Andrea ZucaliArmando Santoro
Jan 22, 2009·Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen·F Lordick
Jul 17, 2010·Sarcoma·Robert GrimerBeatrice Seddon
Jan 30, 2015·Clinical Sarcoma Research·Roberta SanfilippoPaolo Giovanni Casali
Aug 11, 2017·Therapeutic Advances in Medical Oncology·Gino K InWilliam W Tseng
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A YovineJ L Misset
Feb 24, 2006·International Journal of Cancer. Journal International Du Cancer·Jacques-Olivier BayUNKNOWN Groupe Sarcome Français
Jun 3, 2011·Current Oncology Reports·Sherif S Morgan, Lee D Cranmer
May 15, 2013·Journal of Cancer Research and Clinical Oncology·F PlonerT Brodowicz
Jun 5, 2015·Future Oncology·Giovanni GrignaniPeter Reichardt
Nov 29, 2016·Clinical Sarcoma Research·Adam DangoorIan Judson
Mar 13, 2012·Clinical Medicine Insights. Oncology·Jin Lee, Colin McGuire
Oct 5, 2017·Therapeutic Advances in Medical Oncology·Jenna S BlelochSharon Prince
Nov 3, 2007·Mayo Clinic Proceedings·Keith M Skubitz, David R D'Adamo
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M Eriksson

❮ Previous
Next ❯

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.